Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

Keegan, Mark; König, F.; McClelland, Robyn L.; Brück, Wolfgang; Morales, Yazmín; Bitsch, Andreas; Panitch, Hillel S.; Lassmann, Hans; Weinshenker, Brian G.; Rodriguez, Moses; Parisi, Joseph E.; Lucchinetti, Claudia F.

doi:10.1016/s0140-6736(05)67102-4

Cited by 398 publications

(295 citation statements)

References 6 publications

Supporting

Mentioning

257

Contrasting

Unclassified

Order By: Relevance

“…Our results support a pathogenic role for oxidized derivatives of cholesterol and identify PARP as a target for therapeutic intervention in pattern I MS pathology. Furthermore, from a clinical standpoint patients with pattern II, but not I, have been reported to respond to plasmapheresis (35). Thus, the antibody signatures we have identified may be useful for identifying patients that would be responsive to treatment with plasmapheresis.…”

Section: Discussionmentioning

confidence: 94%

Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis

Quintana

Farez

Viglietta

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

226

213

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic relapsing disease of the central nervous system (CNS) in which immune processes are believed to play a major role. To date, there is no reliable method by which to characterize the immune processes and their changes associated with different forms of MS and disease progression. We performed antigen microarray analysis to characterize patterns of antibody reactivity in MS serum against a panel of CNS protein and lipid autoantigens and heat shock proteins. Informatic analysis consisted of a training set that was validated on a blinded test set. The results were further validated on an independent cohort of relapsing-remitting (RRMS) samples. We found unique autoantibody patterns that distinguished RRMS, secondary progressive (SPMS), and primary progressive (PPMS) MS from both healthy controls and other neurologic or autoimmune driven diseases including Alzheimer's disease, adrenoleukodystropy, and lupus erythematosus. RRMS was characterized by autoantibodies to heat shock proteins that were not observed in PPMS or SPMS. In addition, RRMS, SPMS, and PPMS were characterized by unique patterns of reactivity to CNS antigens. Furthermore, we examined sera from patients with different immunopathologic patterns of MS as determined by brain biopsy, and we identified unique antibody patterns to lipids and CNS-derived peptides that were linked to each type of pathology. The demonstration of unique serum immune signatures linked to different stages and pathologic processes in MS provides an avenue to monitor MS and to characterize immunopathogenic mechanisms and therapeutic targets in the disease.antibodies ͉ autoimmunity ͉ biomarker

show abstract

Section: Discussionmentioning

confidence: 94%

Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis

Quintana

Farez

Viglietta

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

226

213

View full text Add to dashboard Cite

show abstract

“…This could also partly explain the disassociation between relapses and the presence of enhancing lesions, 5 in which relapses are commonly accompanied with enhancing lesions but not vice versa. Evidence is also surfacing that response to therapy varies with (immunopathologic) subtype of a lesion, 26 which further invites the search for in vivo surrogates capable of dissociating the presence of inflammation from its true effect on irreversible destruction of tissue.…”

Section: Is Inflammation Indicative Of Destruction or Repair?mentioning

confidence: 99%

MR Imaging Intensity Modeling of Damage and Repair In Multiple Sclerosis: Relationship of Short-Term Lesion Recovery to Progression and Disability

Meier¹,

Weiner²,

Guttmann³

2007

American Journal of Neuroradiology

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE: Formation of lesions in multiple sclerosis (MS) shows pronounced short-term fluctuation of MR imaging hyperintensity and size, a qualitatively known but poorly characterized phenomenon. With the use of time-series modeling of MR imaging intensity, our study relates the short-term dynamics of new T2 lesion formation to those of contrast enhancement and markers of long-term progression of disease.

show abstract

“…The efficacy of TPE for relapsing-remitting MS and other inflammatory demyelinating diseases was demonstrated in a randomized, controlled trial and several uncontrolled studies [36][37][38][39][40]. TPE was also reported to be beneficial for NMOSD attacks [40][41][42][43].…”

Section: Treatment Of Nmosd Attacksmentioning

confidence: 96%

Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders

Kleiter

Gold

2016

Neurotherapeutics

View full text Add to dashboard Cite

Neuromyelitis optica spectrum disorders (NMOSD) are important evolving entities, which have reached much attention in the recent years. NMOSD are characterized by inflammatory lesions in the optic nerves, spinal cord, and central parts of the brain, as well as an autoimmune process directed against aquaporin-4. As disability in NMOSD accumulates by inflammatory damage from attacks, both the treatment and prevention of attacks are decisive for the long-term outcome. NMOSD attacks are treated with highdose intravenous corticosteroids and apheresis therapies, in particular therapeutic plasma exchange. In cases of incomplete remission, escalation of attack treatment is recommended. Preventive therapy is immunosuppressive and should by commenced as early as possible. Apart from classical immunosuppressants such as azathioprine and mycophenolate mofetil, repurposed biologicals are increasingly used. B-cell depletion with rituximab and other agents, inhibition of the interleukin-6 receptor with tocilizumab, and blockade of complement-mediated damage by eculizumab all are promising therapeutic strategies evaluated in randomized controlled trials. In this review, we will discuss present and future immunotherapies for NMOSD and also consider combination of treatments, plasma, cellular and other therapies. Current advances in immunopathological knowledge are translated into innovative concepts and begin a new era of NMOSD therapy.

show abstract

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

Cited by 398 publications

References 6 publications

Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis

Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis

MR Imaging Intensity Modeling of Damage and Repair In Multiple Sclerosis: Relationship of Short-Term Lesion Recovery to Progression and Disability

Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders

Contact Info

Product

Resources

About